ImageneBio Inc
Support and Resistance Levels
Past performance
News About IMA
All events for IMA
All deals for IMA
Financial Ratios
Financial Statements
IMA vs Sector & Peers
About ImageneBio Inc
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis. Website inmagenebio.com
Headquarters San Diego, CA, US